Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2617305
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Patients receive FOLFIRI with bevacizumab (Treatment will be continued unless the disease progression, unacceptable toxicity, or consent withdrawal.)
Primary outcome(s): Efficacy: Response rate
Study Design: Single arm Non-randomized
创建时间：
2009-04-15
